← SynDRA
FIRMONERTINIB
SynDRA canonical compound SYN0039439 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | protein tyrosine kinase inhibitor |
|---|
| Indication | non-small cell lung cancer (nsclc) |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
- tyrosine kinase inhibitor
Cross-references
Synonyms
- Alflutinib
- Furmonertinib
- AFU
- AST-2818
- AST2818
- furmonertinib
- AST 2818
- A49A7A5YN4
- RefChem:915390
- Aflutinib
- Alflutinib(AST2818;AST-2818;ASK120067)
- Alflutinib?
- firmonertinib [INN]
- alflutinib (pseudo INN)
- Firmonertinib [WHO-DD]
- Firmonertinib (USAN/INN)
- FIRMONERTINIB [USAN]
- UNII-A49A7A5YN4
- ASTX-295
- orb1306046
- SCHEMBL17490447
- SCHEMBL29386562
- GTPL10477
- GHKOONMJXNWOIW-UHFFFAOYSA-N
- UZC05783
- example 3 [US10072002B2]
- NSC856804
- AKOS040745008
- AT42596
- EX-A2868-1
- NSC-856804
- NCGC00878597-01
- AC-36862
- TS-08244
- HY-112870
- D12956
- T22254
- Alflutinib, AST-2818, AST2818, AST 2818
Look up FIRMONERTINIB in the interactive SynDRA portal →